
About Brooks Laboratories
Brooks Laboratories is a publicly listed company based in Chandigarh (India) founded in 2002. Manufacturer of pharmaceutical injectables, tablets, and oral suspensions. The company has 499 employees. Its chief executive, as recorded, is Rajnish Kumar Bedi. Its Indian entity Brooks Laboratories Limited reported revenue of ₹106 Cr. Brooks Laboratories offers products and services including Antibiotics and Injections. Its focus areas include Traditional Pharmaceuticals, Generics and Diversified.
Company details
Founded in 2002 and based in Chandigarh, India, the company operates in the pharmaceutical sector. Formulations across therapeutic areas such as antibiotics and pain management are developed, manufactured, and marketed. Products, including injectables, tablets, and oral suspensions, are distributed domestically and internationally. GMP certifications and accreditations are held, with manufacturing processes maintained under strict quality control standards.
- Headquarters Chandigarh, India
- Employees 499
- Stage Public
- SectorsHealthcare
- Email••••••••
- Website brookslabs.net
- Social LinkedIn Instagram
- Legal Name Brooks Laboratories Limited
- Market Cap₹197 Cr
BROOKS · NSE
- Share Price₹67.30
+0.51% today
- Revenue₹85.74 Cr
FY 2025-26 · +3.9% YoY
- EBITDA₹7.07 Cr
Margin 8.2%
- Net Profit₹24.30 Cr
FY 2025-26 · +343.2% YoY
- P/E (TTM)59.5x
P/B 1.1x
- Employee Count499
Associated legal entities of Brooks Laboratories
Brooks Laboratories operates through Brooks Laboratories Limited, a listed company (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2026) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Brooks Laboratories Limited Listed CIN L24232HP2002PLC000267 | Active | 23 Jan 2002 | Nalagarh, Himachal Pradesh | ₹106 Cr | 289 | 8 | View details |
Products & Services of Brooks Laboratories
Brooks Laboratories offers a comprehensive portfolio of products and services, including Antibiotics and Injections.
Antibiotics and related formulations are manufactured and distributed for therapeutic use.
Liquid, dry powder, and lyophilized injections are produced for various medical applications.
Board of directors of Brooks Laboratories Limited (Brooks Laboratories)
Brooks Laboratories Limited is the primary company behind Brooks Laboratories. The board of Brooks Laboratories Limited currently have 6 directors; the longest-serving is Jitendrapratap Rambahadur Singh, appointed in 2022. 22 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Jitendrapratap Rambahadur Singh DIN 09796568 | Whole-time director | 23 Nov 2022 | 3 yrs 11 mo | Brooks Laboratories Limited |
| Durga Shankar Maity DIN 03136361 | Whole-time director | 07 Jul 2023 | 3 yrs 4 mo | Brooks Laboratories Limited |
| Bhushan Singh Rana DIN 10289384 | Whole-time director | 23 Aug 2023 | 3 yrs 2 mo | Brooks Laboratories Limited |
| Lalit Mahajan DIN 03270819 | Director | 07 Aug 2024 | 2 yrs 3 mo | Brooks Laboratories Limited |
| Usha Singh DIN 10706734 | Director | 07 Aug 2024 | 2 yrs 3 mo | Brooks Laboratories Limited |
| Manav Mahajan DIN 10721554 | Director | 28 Sep 2024 | 2 yrs 1 mo | Brooks Laboratories Limited |
People of Brooks Laboratories
1 people are tracked at Brooks Laboratories (1 in leadership); the tracked headcount is 499.
| Name | Role | Group |
|---|---|---|
| Chairman & CEO | Leadership |
Complete people profiles for Brooks Laboratories
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Brooks Laboratories
Brooks Laboratories is a publicly listed company on the NSE with ticker symbol BROOKS in India, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date05 Sep 2011
- Listed onBSE: 533543 · NSE: BROOKS
- Listed entityBrooks Laboratories Limited
- Exchange sectorHealth technology
- ISININE650L01011
- Share price₹68.72 (+6.11% on the day) · 2026-10-14
- Market capitalisation₹191 Cr
- Price to earnings15.3
- EPS (diluted, trailing year)₹4.49
- Volume (last session)214,839
Financials of Brooks Laboratories
Exchange-reported figures of Brooks Laboratories Limited, the listed company behind Brooks Laboratories (NSE: BROOKS).
Financial Highlights
FY 2025-26 · ConsolidatedRevenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Revenue | 85.74 | 82.56 | 79.49 | 63.20 | 91.18 | 77.25 |
| Revenue growth | +3.9% | +3.9% | +25.8% | -30.7% | +18.0% | - |
| EBITDA | 7.07 | (8.04) | (17.86) | (29.72) | (14.27) | 0.53 |
| EBITDA margin | +8.3% | -9.7% | -22.5% | -47.0% | -15.7% | +0.7% |
| Profit before tax | 24.59 | (9.79) | (19.55) | (38.36) | (23.92) | (8.97) |
| Net profit | 24.30 | (9.99) | (19.59) | (21.25) | (11.44) | (19.31) |
| Net profit margin | +28.3% | -12.1% | -24.6% | -33.6% | -12.6% | -25.0% |
| EPS (₹) | 8.35 | (3.38) | (7.46) | (8.46) | (4.57) | (7.84) |
| Balance sheet | ||||||
| Total assets | 133 | 107 | 72.68 | 82.49 | 162 | 112 |
| Net worth | 123 | 98.11 | 65.59 | 73.95 | 87.49 | 79.15 |
| Total debt | 8.52 | 7.58 | 5.64 | 6.51 | 25.26 | 31.38 |
| Cash & bank | 7.55 | 1.25 | 0.69 | 1.08 | 3.81 | 1.70 |
| Net working capital | 22.01 | 17.24 | 13.29 | 0.49 | 27.43 | 0.69 |
| Cash flow | ||||||
| Cash from operations | 9.29 | 2.63 | (9.80) | (14.49) | (37.44) | 4.46 |
| Cash from investing | (2.92) | (45.14) | 0.18 | 0.49 | (24.91) | (5.13) |
| Cash from financing | 0.17 | 42.43 | 9.72 | 11.41 | 64.07 | 1.16 |
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 19.25 | 22.96 | 20.21 | 16.57 | 23.45 | 25.51 | 23.32 | 20.52 |
| Revenue growth (YoY) | -17.9% | -10.0% | -13.3% | -19.3% | +12.8% | +42.3% | - | - |
| Other income | 75.68 | 0.18 | 1.35 | 5.32 | 6.13 | 7.15 | 0.62 | 0.03 |
| EBITDA | (2.06) | (1.34) | 0.68 | 0.74 | 2.52 | 3.12 | (1.25) | (1.49) |
| EBITDA margin | -10.7% | -5.8% | +3.4% | +4.5% | +10.7% | +12.2% | -5.4% | -7.3% |
| Depreciation | 0.45 | 0.42 | 0.41 | 0.39 | 0.39 | 0.39 | 0.39 | 0.38 |
| Interest | 0.25 | 0.21 | 0.09 | 0.16 | 0.28 | 0.30 | 0.26 | 0.28 |
| Profit before tax | 72.92 | (1.79) | 1.53 | 5.51 | 7.98 | 9.58 | (1.28) | (2.12) |
| Tax | 5.32 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.18 | 0.00 |
| Net profit | 67.60 | (1.79) | 1.53 | 5.51 | 7.98 | 9.58 | (1.46) | (2.12) |
| EPS (₹) | 22.95 | (0.61) | 0.52 | 1.87 | 2.71 | 3.25 | (0.54) | (0.82) |
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 85.74 | 82.56 | 79.49 | 55.54 | 76.97 | 77.27 | 69.69 |
| Revenue growth | +3.9% | +3.9% | +43.1% | -27.8% | -0.4% | +10.9% | - |
| EBITDA | 7.07 | 4.98 | 3.26 | (5.81) | 1.88 | 0.94 | (3.92) |
| EBITDA margin | +8.3% | +6.0% | +4.1% | -10.5% | +2.4% | +1.2% | -5.6% |
| Profit before tax | 5.81 | 3.23 | 1.57 | (8.18) | 0.67 | (8.44) | (13.51) |
| Net profit | 5.52 | 3.03 | 1.53 | (8.19) | 0.41 | (15.53) | (23.19) |
| Net profit margin | +6.4% | +3.7% | +1.9% | -14.8% | +0.5% | -20.1% | -33.3% |
| EPS (₹) | 1.97 | 1.04 | 0.58 | (3.31) | 0.27 | (6.31) | (9.87) |
| Balance sheet | |||||||
| Total assets | 131 | 124 | 76.63 | 65.31 | 73.11 | 74.37 | 128 |
| Net worth | 121 | 115 | 69.53 | 56.78 | 65.00 | 64.21 | 98.41 |
| Total debt | 8.52 | 7.58 | 5.64 | 6.51 | 5.97 | 8.40 | 27.64 |
| Cash & bank | 7.55 | 1.25 | 0.69 | 1.08 | 1.08 | 0.88 | 1.53 |
| Net working capital | 22.01 | 17.24 | 13.29 | 0.49 | 6.69 | 6.71 | 7.82 |
| Cash flow | |||||||
| Cash from operations | 9.29 | 2.63 | (9.80) | 0.55 | 3.12 | (0.90) | (9.39) |
| Cash from investing | (2.92) | (45.14) | 0.18 | (0.40) | 1.12 | (0.74) | (2.33) |
| Cash from financing | 0.17 | 42.43 | 9.72 | (0.21) | (4.22) | 1.31 | 9.61 |
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 19.25 | 22.96 | 20.21 | 16.57 | 23.45 | 25.51 | 23.32 | 20.52 |
| Revenue growth (YoY) | -17.9% | -10.0% | -13.3% | -19.3% | +12.8% | +42.3% | - | - |
| Other income | 75.68 | 0.18 | 0.44 | 0.13 | 0.39 | 0.22 | 0.62 | 0.03 |
| Total expenses | 18.93 | 21.10 | 19.53 | 15.83 | 20.93 | 22.39 | 21.74 | 18.94 |
| EBITDA | 0.32 | 1.86 | 0.68 | 0.74 | 2.52 | 3.12 | 1.58 | 1.58 |
| EBITDA margin | +1.7% | +8.1% | +3.4% | +4.5% | +10.7% | +12.2% | +6.8% | +7.7% |
| Depreciation | 0.45 | 0.42 | 0.41 | 0.39 | 0.39 | 0.39 | 0.39 | 0.38 |
| Interest | 0.25 | 0.21 | 0.09 | 0.16 | 0.28 | 0.30 | 0.26 | 0.28 |
| Profit before tax | 75.30 | 1.41 | 0.62 | 0.32 | 2.24 | 2.65 | 1.55 | 0.95 |
| Tax | 5.32 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.18 | 0.00 |
Financial Statements
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 19.25 | 22.96 | 20.21 | 16.57 | 23.45 | 25.51 | 23.32 | 20.52 |
| Revenue growth (YoY) | -17.9% | -10.0% | -13.3% | -19.3% | +12.8% | +42.3% | - | - |
| Other income | 75.68 | 0.18 | 1.35 | 5.32 | 6.13 | 7.15 | 0.62 | 0.03 |
| EBITDA | (2.06) | (1.34) | 0.68 | 0.74 | 2.52 | 3.12 | (1.25) | (1.49) |
| EBITDA margin | -10.7% | -5.8% | +3.4% | +4.5% | +10.7% | +12.2% | -5.4% | -7.3% |
| Depreciation | 0.45 | 0.42 | 0.41 | 0.39 | 0.39 | 0.39 | 0.39 | 0.38 |
| Interest | 0.25 | 0.21 | 0.09 | 0.16 | 0.28 | 0.30 | 0.26 | 0.28 |
| Profit before tax | 72.92 | (1.79) | 1.53 | 5.51 | 7.98 | 9.58 | (1.28) | (2.12) |
| Tax | 5.32 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.18 | 0.00 |
| Net profit | 67.60 | (1.79) | 1.53 | 5.51 | 7.98 | 9.58 | (1.46) | (2.12) |
| EPS (₹) | 22.95 | (0.61) | 0.52 | 1.87 | 2.71 | 3.25 | (0.54) | (0.82) |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|---|
| Revenue | 85.74 | 82.56 | 79.49 | 63.20 | 91.18 | 77.25 |
| Revenue growth | +3.9% | +3.9% | +25.8% | -30.7% | +18.0% | - |
| Other income | 19.95 | 0.88 | 0.92 | 0.57 | 0.80 | 0.74 |
| Total expenses | 78.67 | 90.60 | 97.35 | 92.92 | 105 | 76.72 |
| Employee cost | 14.62 | 12.45 | 10.09 | 16.00 | 16.85 | 12.04 |
| EBITDA | 7.07 | (8.04) | (17.86) | (29.72) | (14.27) | 0.53 |
| EBITDA margin | +8.3% | -9.7% | -22.5% | -47.0% | -15.7% | +0.7% |
| Depreciation | 1.59 | 1.60 | 1.77 | 7.03 | 7.35 | 7.14 |
| Interest | 0.84 | 1.03 | 0.84 | 2.18 | 3.10 | 3.10 |
| Profit before tax | 24.59 | (9.79) | (19.55) | (38.36) | (23.92) | (8.97) |
| Tax | 0.00 | 0.18 | 0.03 | (7.32) | (4.59) | 10.38 |
| Net profit | 24.30 | (9.99) | (19.59) | (21.25) | (11.44) | (19.31) |
| Net profit margin | +28.3% | -12.1% | -24.6% | -33.6% | -12.6% | -25.0% |
| EPS (₹) | 8.35 | (3.38) | (7.46) | (8.46) | (4.57) | (7.84) |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|---|
| Equity & liabilities | ||||||
| Share capital | 29.46 | 29.46 | 26.25 | 24.70 | 24.70 | 24.70 |
| Reserves & surplus | 93.20 | 68.65 | 39.34 | 49.25 | 62.79 | 54.45 |
| Shareholders' funds (net worth) | 123 | 98.11 | 65.59 | 73.95 | 87.49 | 79.15 |
| Minority interest | 0.00 | 0.00 | 0.00 | 0.00 | 46.83 | 0.00 |
| Secured loans | 7.28 | 6.06 | 5.04 | 5.66 | 24.21 | 31.38 |
| Unsecured loans | 1.24 | 1.52 | 0.60 | 0.85 | 1.05 | 0.00 |
| Total debt | 8.52 | 7.58 | 5.64 | 6.51 | 25.26 | 31.38 |
| Total liabilities | 133 | 107 | 72.68 | 82.49 | 162 | 112 |
| Assets | ||||||
| Gross block | 26.00 | 25.15 | 23.27 | 22.83 | 143 | 133 |
| Net block | 14.52 | 13.98 | 13.67 | 15.00 | 110 | 108 |
| Capital work in progress | 1.19 | 0.00 | 0.00 | 0.00 | 15.11 | 0.83 |
| Investments | 92.34 | 73.55 | 42.91 | 64.03 | 0.06 | 0.02 |
| Inventories | 11.02 | 9.20 | 9.61 | 11.30 | 27.52 | 23.60 |
| Sundry debtors | 16.11 | 19.99 | 16.32 | 12.75 | 17.66 | 13.70 |
| Cash & bank balances | 7.55 | 1.25 | 0.69 | 1.08 | 3.81 | 1.70 |
| Loans & advances | 2.73 | 3.43 | 4.43 | 2.47 | 12.19 | 8.36 |
| Total current assets | 37.41 | 33.87 | 31.05 | 27.60 | 61.18 | 47.36 |
| Total current liabilities | 15.40 | 16.63 | 17.76 | 27.11 | 33.75 | 46.67 |
| Net working capital | 22.01 | 17.24 | 13.29 | 0.49 | 27.43 | 0.69 |
| Total assets | 133 | 107 | 72.68 | 82.49 | 162 | 112 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|---|
| Opening cash | 0.04 | 0.13 | 0.02 | 2.61 | 0.88 | 0.40 |
| Net cash from operating activities | 9.29 | 2.63 | (9.80) | (14.49) | (37.44) | 4.46 |
| Net cash from investing activities | (2.92) | (45.14) | 0.18 | 0.49 | (24.91) | (5.13) |
| Net cash from financing activities | 0.17 | 42.43 | 9.72 | 11.41 | 64.07 | 1.16 |
| Net change in cash | 6.54 | (0.08) | 0.10 | (2.58) | 1.72 | 0.49 |
| Closing cash | 7.55 | 1.25 | 0.69 | 1.08 | 3.81 | 1.70 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|---|
| Growth | ||||||
| Sales growth | +3.9% | +3.9% | +25.8% | -30.7% | +18.0% | - |
| EBITDA growth | +187.9% | +55.0% | +39.9% | -108.3% | -2792.5% | - |
| PBT growth | +9998.0% | +49.9% | +49.0% | -60.4% | -166.7% | +9997.0% |
| Net income growth | +343.2% | +49.0% | +7.8% | -85.8% | +40.8% | - |
| Revenue CAGR (3Y) | +10.7% | -3.3% | +1.0% | - | - | - |
| EBITDA CAGR (3Y) | - | -17.4% | - | - | - | - |
| Profitability & leverage | ||||||
| Net income margin | +28.7% | -12.1% | -24.6% | -49.1% | -21.2% | -25.1% |
| Return on capital employed | - | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Return on net worth | - | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Debt / equity | - | 0.08 | 0.09 | 0.20 | 0.40 | 0.40 |
| Long-term debt / equity | - | 0.01 | 0.01 | 0.07 | 0.17 | 0.18 |
| Interest cover | 15.33 | -10.68 | -4.28 | -5.93 | -14.34 | -46.90 |
| Efficiency & per share | ||||||
| Fixed asset turnover | - | 3.41 | 3.45 | 0.76 | 0.66 | 0.58 |
| Inventory turnover | - | 8.78 | 7.60 | 3.26 | 3.56 | 3.27 |
| Debtors turnover | - | 4.55 | 5.47 | 4.16 | 5.81 | 5.64 |
| EPS (₹) | 8.35 | (3.38) | (7.46) | (8.46) | (4.57) | (7.84) |
| Dividend per share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | 41.64 | 33.30 | 24.99 | 29.94 | 35.42 | 32.04 |
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 19.25 | 22.96 | 20.21 | 16.57 | 23.45 | 25.51 | 23.32 | 20.52 |
| Revenue growth (YoY) | -17.9% | -10.0% | -13.3% | -19.3% | +12.8% | +42.3% | - | - |
| Other income | 75.68 | 0.18 | 0.44 | 0.13 | 0.39 | 0.22 | 0.62 | 0.03 |
| Total expenses | 18.93 | 21.10 | 19.53 | 15.83 | 20.93 | 22.39 | 21.74 | 18.94 |
| EBITDA | 0.32 | 1.86 | 0.68 | 0.74 | 2.52 | 3.12 | 1.58 | 1.58 |
| EBITDA margin | +1.7% | +8.1% | +3.4% | +4.5% | +10.7% | +12.2% | +6.8% | +7.7% |
| Depreciation | 0.45 | 0.42 | 0.41 | 0.39 | 0.39 | 0.39 | 0.39 | 0.38 |
| Interest | 0.25 | 0.21 | 0.09 | 0.16 | 0.28 | 0.30 | 0.26 | 0.28 |
| Profit before tax | 75.30 | 1.41 | 0.62 | 0.32 | 2.24 | 2.65 | 1.55 | 0.95 |
| Tax | 5.32 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.18 | 0.00 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 85.74 | 82.56 | 79.49 | 55.54 | 76.97 | 77.27 | 69.69 |
| Revenue growth | +3.9% | +3.9% | +43.1% | -27.8% | -0.4% | +10.9% | - |
| Other income | 1.17 | 0.88 | 0.92 | 0.12 | 0.95 | 0.96 | 0.41 |
| Total expenses | 78.67 | 77.58 | 76.23 | 61.35 | 75.09 | 76.33 | 73.61 |
| Employee cost | 14.62 | 12.45 | 10.09 | 10.65 | 10.88 | 12.04 | 11.16 |
| EBITDA | 7.07 | 4.98 | 3.26 | (5.81) | 1.88 | 0.94 | (3.92) |
| EBITDA margin | +8.3% | +6.0% | +4.1% | -10.5% | +2.4% | +1.2% | -5.6% |
| Depreciation | 1.59 | 1.60 | 1.77 | 1.72 | 1.49 | 7.09 | 6.65 |
| Interest | 0.84 | 1.03 | 0.84 | 0.77 | 0.67 | 3.25 | 3.35 |
| Profit before tax | 5.81 | 3.23 | 1.57 | (8.18) | 0.67 | (8.44) | (13.51) |
| Tax | 0.00 | 0.18 | 0.03 | 0.00 | 0.00 | 7.15 | 10.86 |
| Net profit | 5.52 | 3.03 | 1.53 | (8.19) | 0.41 | (15.53) | (23.19) |
| Net profit margin | +6.4% | +3.7% | +1.9% | -14.8% | +0.5% | -20.1% | -33.3% |
| EPS (₹) | 1.97 | 1.04 | 0.58 | (3.31) | 0.27 | (6.31) | (9.87) |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 29.46 | 29.46 | 26.25 | 24.70 | 24.70 | 24.70 | 24.70 |
| Reserves & surplus | 91.39 | 85.61 | 43.28 | 32.08 | 40.30 | 39.51 | 73.71 |
| Shareholders' funds (net worth) | 121 | 115 | 69.53 | 56.78 | 65.00 | 64.21 | 98.41 |
| Secured loans | 7.28 | 6.06 | 5.04 | 5.66 | 4.92 | 8.40 | 26.88 |
| Unsecured loans | 1.24 | 1.52 | 0.60 | 0.85 | 1.05 | 0.00 | 0.76 |
| Total debt | 8.52 | 7.58 | 5.64 | 6.51 | 5.97 | 8.40 | 27.64 |
| Total liabilities | 131 | 124 | 76.63 | 65.31 | 73.11 | 74.37 | 128 |
| Assets | |||||||
| Gross block | 26.00 | 25.15 | 23.27 | 22.83 | 21.07 | 19.64 | 133 |
| Net block | 14.52 | 13.98 | 13.67 | 15.00 | 15.14 | 14.96 | 113 |
| Capital work in progress | 1.19 | 0.00 | 0.00 | 0.00 | 1.12 | 0.02 | 0.11 |
| Investments | 90.53 | 90.52 | 46.86 | 46.85 | 46.84 | 46.81 | 0.02 |
| Inventories | 11.02 | 9.20 | 9.61 | 11.30 | 16.59 | 12.38 | 13.77 |
| Sundry debtors | 16.11 | 19.99 | 16.32 | 12.75 | 15.03 | 9.59 | 15.56 |
| Cash & bank balances | 7.55 | 1.25 | 0.69 | 1.08 | 1.08 | 0.88 | 1.53 |
| Loans & advances | 2.73 | 3.43 | 4.43 | 2.47 | 4.34 | 2.49 | 7.05 |
| Total current assets | 37.41 | 33.87 | 31.05 | 27.60 | 37.04 | 25.34 | 37.91 |
| Total current liabilities | 15.40 | 16.63 | 17.76 | 27.11 | 30.35 | 18.63 | 30.09 |
| Net working capital | 22.01 | 17.24 | 13.29 | 0.49 | 6.69 | 6.71 | 7.82 |
| Total assets | 131 | 124 | 76.63 | 65.31 | 73.11 | 74.37 | 128 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 0.04 | 0.13 | 0.02 | 0.08 | 0.06 | 0.40 | 2.50 |
| Net cash from operating activities | 9.29 | 2.63 | (9.80) | 0.55 | 3.12 | (0.90) | (9.39) |
| Net cash from investing activities | (2.92) | (45.14) | 0.18 | (0.40) | 1.12 | (0.74) | (2.33) |
| Net cash from financing activities | 0.17 | 42.43 | 9.72 | (0.21) | (4.22) | 1.31 | 9.61 |
| Net change in cash | 6.54 | (0.08) | 0.10 | (0.06) | 0.02 | (0.33) | (2.10) |
| Closing cash | 7.55 | 1.25 | 0.69 | 1.08 | 1.08 | 0.88 | 1.53 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | +3.9% | +3.9% | +43.1% | -27.8% | -0.4% | +10.9% | - |
| EBITDA growth | +42.0% | +52.8% | +156.1% | -409.0% | +100.0% | +124.0% | - |
| PBT growth | +79.9% | +105.7% | +9998.0% | - | +9998.0% | +37.5% | +9.6% |
| Net income growth | +82.2% | +98.0% | +118.7% | -2097.6% | +102.6% | +33.0% | - |
| Revenue CAGR (3Y) | +15.6% | +2.4% | +1.0% | -7.3% | +11.8% | +11.5% | +6.6% |
| EBITDA CAGR (3Y) | - | +38.4% | +51.4% | +14.0% | - | - | - |
| Profitability & leverage | |||||||
| Net income margin | +6.8% | +3.7% | +1.9% | -14.7% | +0.9% | -20.2% | -35.0% |
| Return on capital employed | +4.3% | +3.2% | +2.7% | 0.0% | +1.2% | 0.0% | -7.7% |
| Return on net worth | +4.0% | +2.4% | +1.9% | 0.0% | +0.5% | 0.0% | -24.0% |
| Debt / equity | 0.07 | 0.07 | 0.10 | 0.10 | 0.11 | 0.22 | 0.29 |
| Long-term debt / equity | 0.01 | 0.01 | 0.01 | 0.01 | 0.02 | 0.08 | 0.13 |
| Interest cover | 15.33 | 30.47 | 56.38 | -10.23 | 171.79 | -52.85 | -31.69 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 3.35 | 3.41 | 3.45 | 2.53 | 3.78 | 1.02 | 0.53 |
| Inventory turnover | 8.48 | 8.78 | 7.60 | 3.98 | 5.31 | 5.91 | 5.85 |
| Debtors turnover | 4.75 | 4.55 | 5.47 | 4.00 | 6.25 | 6.14 | 5.17 |
| EPS (₹) | 1.97 | 1.04 | 0.58 | (3.31) | 0.27 | (6.31) | (9.87) |
| Dividend per share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | 41.02 | 39.06 | 26.49 | 22.98 | 26.31 | 25.99 | 39.84 |
Web traffic of Brooks Laboratories
The website of Brooks Laboratories (brookslabs.net) receives about 1.2K visits a month.
- Monthly visits1.2K
▼ 8.4% vs previous month
Top companies in Traditional Health & Nutrition
3 companies that operate in the same segment as Brooks Laboratories (Traditional Health & Nutrition) in India, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Oral solid drug delivery systems are manufactured and developed. | 1985 | Mumbai, Maharashtra, India | USD 42.49 M | USD 72.52 M | 1,115 | |
Generic, semi-solid, and liquid dosage forms are manufactured. | 1990 | Bengaluru, Karnataka, India | USD 508.93 M | 4,050 | ||
Specialty generic pharmaceuticals and APIs are manufactured and marketed. | 1983 | Mumbai, Maharashtra, India | USD 6.44 B | 19,801 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Brooks Laboratories
Complete news archive for Brooks Laboratories
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Brooks Laboratories
Brooks Laboratories was founded in 2002.
Brooks Laboratories is headquartered in Chandigarh, India.
Rajnish Kumar Bedi is the CEO of Brooks Laboratories, as recorded in our data.
Brooks Laboratories has 499 employees.
The primary company behind Brooks Laboratories, Brooks Laboratories Limited, reported revenue of ₹106 Cr for FY 2026, up 4% year on year.
Founded in 2002 and based in Chandigarh, India, the company operates in the pharmaceutical sector. Formulations across therapeutic areas such as antibiotics and pain management are developed, manufactured, and marketed. Products, including injectables, tablets, and oral suspensions, are distributed domestically and internationally. GMP certifications and accreditations are held, with manufacturing processes maintained under strict quality control standards.
Brooks Laboratories offers Antibiotics and Injections.
Yes, Brooks Laboratories is publicly traded on NSE under the ticker symbol BROOKS.
Brooks Laboratories operates through Brooks Laboratories Limited.
The legal entities of Brooks Laboratories currently have 8 directors, including Prashant Rathi, Jitendrapratap Rambahadur Singh, Krutika Mohan Rane and others.
